Skip to main content
main-content
Erschienen in: hautnah dermatologie 2/2022

22.03.2022 | Neutrophile Dermatosen | Zertifizierte Fortbildung

Fehlreguliertes angeborenes Immunsystem

Neutrophile Dermatosen

verfasst von: Steffen Schrenker, Prof. Dr. med. Luise Erpenbeck

Erschienen in: hautnah dermatologie | Ausgabe 2/2022

zum CME-Kurs Einloggen, um Zugang zu erhalten

Auszug

Die neutrophilen Dermatosen sind aufgrund ihres vielfältigen Erscheinungsbilds klinisch herausfordernd. Trotz der Variabilität in Klinik und Histologie finden sich überschneidende pathogenetische Merkmale zwischen den Krankheitsentitäten wie Sweet-Syndrom oder Pyoderma gangraenosum. Ein besseres Verständnis der pathogenetischen und funktionellen Gemeinsamkeiten ist unumgänglich, um Ansatzpunkte für Biologika zu identifizieren, die etablierte Therapien ergänzen oder ablösen könnten. …
Literatur
1.
Zurück zum Zitat Villarreal-Villarreal C et al. Sweet syndrome: a review and update. Actas dermo-sifiliograficas. 2016; 107: 369-78 Villarreal-Villarreal C et al. Sweet syndrome: a review and update. Actas dermo-sifiliograficas. 2016; 107: 369-78
2.
Zurück zum Zitat Agarwal A et al. Refractory Subcutaneous Sweet Syndrome Treated With Adalimumab. JAMA Dermatol. 2016; 152: 842-4 Agarwal A et al. Refractory Subcutaneous Sweet Syndrome Treated With Adalimumab. JAMA Dermatol. 2016; 152: 842-4
3.
Zurück zum Zitat Reuss-Borst MA et al. The possible role of G-CSF in the pathogenesis of Sweet's syndrome. Leuk Lymphoma. 1994; 15: 261-4 Reuss-Borst MA et al. The possible role of G-CSF in the pathogenesis of Sweet's syndrome. Leuk Lymphoma. 1994; 15: 261-4
4.
Zurück zum Zitat Kawakami T et al. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol. 2004; 140: 570-4 Kawakami T et al. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol. 2004; 140: 570-4
5.
Zurück zum Zitat Patterson J et al. The vasculopathic reaction pattern. Weedon's Skin Pathology 4th ed Philadelphia, PA: Elsevier Churchill Livingstone. 2016. Patterson J et al. The vasculopathic reaction pattern. Weedon's Skin Pathology 4th ed Philadelphia, PA: Elsevier Churchill Livingstone. 2016.
6.
Zurück zum Zitat Croia C et al. Evaluation of neutrophil extracellular trap deregulated formation in pyoderma gangrenosum. Exp Dermatol. 2021; 30: 1340-4 Croia C et al. Evaluation of neutrophil extracellular trap deregulated formation in pyoderma gangrenosum. Exp Dermatol. 2021; 30: 1340-4
7.
Zurück zum Zitat Bonnekoh H et al. Skin and Systemic Inflammation in Schnitzler's Syndrome Are Associated With Neutrophil Extracellular Trap Formation. Front Immunol. 2019; 10: 546 Bonnekoh H et al. Skin and Systemic Inflammation in Schnitzler's Syndrome Are Associated With Neutrophil Extracellular Trap Formation. Front Immunol. 2019; 10: 546
8.
Zurück zum Zitat Heath MS et al. Insights Into the Pathogenesis of Sweet's Syndrome. Front Immunol. 2019; 10: 414 Heath MS et al. Insights Into the Pathogenesis of Sweet's Syndrome. Front Immunol. 2019; 10: 414
9.
Zurück zum Zitat Takahama H et al. Neutrophilic dermatosis of the dorsal hands: a case showing HLA B54, the marker of Sweet's syndrome. Int J Dermatol. 2010; 49: 1079-80 Takahama H et al. Neutrophilic dermatosis of the dorsal hands: a case showing HLA B54, the marker of Sweet's syndrome. Int J Dermatol. 2010; 49: 1079-80
10.
Zurück zum Zitat von den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994; 31: 535-56; quiz 557-60 von den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994; 31: 535-56; quiz 557-60
11.
Zurück zum Zitat Su WP et al. Diagnostic criteria for Sweet's syndrome. Cutis. 1986; 37: 167-74 Su WP et al. Diagnostic criteria for Sweet's syndrome. Cutis. 1986; 37: 167-74
12.
Zurück zum Zitat Cohen PR et al. Sweet's syndrome and cancer. Clin Dermatol. 1993; 11: 149-57 Cohen PR et al. Sweet's syndrome and cancer. Clin Dermatol. 1993; 11: 149-57
13.
Zurück zum Zitat Raza S et al. Insight into Sweet's syndrome and associated-malignancy: a review of the current literature. Int J Oncol. 2013; 42: 1516-22 Raza S et al. Insight into Sweet's syndrome and associated-malignancy: a review of the current literature. Int J Oncol. 2013; 42: 1516-22
14.
Zurück zum Zitat Sujobert P et al. Evidence of differentiation in myeloid malignancies associated neutrophilic dermatosis: a fluorescent in situ hybridization study of 14 patients. J Invest Dermatol. 2013; 133: 1111-4 Sujobert P et al. Evidence of differentiation in myeloid malignancies associated neutrophilic dermatosis: a fluorescent in situ hybridization study of 14 patients. J Invest Dermatol. 2013; 133: 1111-4
15.
Zurück zum Zitat Aliper AM et al. A role for G-CSF and GM-CSF in nonmyeloid cancers. Cancer Med. 2014; 3: 737-46 Aliper AM et al. A role for G-CSF and GM-CSF in nonmyeloid cancers. Cancer Med. 2014; 3: 737-46
16.
Zurück zum Zitat Stucki A et al. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood. 2001; 97: 2121-9 Stucki A et al. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood. 2001; 97: 2121-9
17.
Zurück zum Zitat Cohen PR et al. Sweet's syndrome: a review of current treatment options. Am J Clin Dermatol. 2002; 3: 117-31 Cohen PR et al. Sweet's syndrome: a review of current treatment options. Am J Clin Dermatol. 2002; 3: 117-31
18.
Zurück zum Zitat Garcovich S et al. Drug management of neutrophilic dermatoses. Expert Rev Clin Pharmacol 2017; 10: 1119-28 Garcovich S et al. Drug management of neutrophilic dermatoses. Expert Rev Clin Pharmacol 2017; 10: 1119-28
19.
Zurück zum Zitat Kluger N et al. Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret®) in a case of refractory Sweet's syndrome. Dermatology. 2011; 222: 123-7 Kluger N et al. Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret®) in a case of refractory Sweet's syndrome. Dermatology. 2011; 222: 123-7
20.
Zurück zum Zitat Marzano AV et al. A Comprehensive Review of Neutrophilic Diseases. Clin Rev Allergy Immunol. 2018; 54: 114-30 Marzano AV et al. A Comprehensive Review of Neutrophilic Diseases. Clin Rev Allergy Immunol. 2018; 54: 114-30
21.
Zurück zum Zitat Su WP et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004; 43: 790-800 Su WP et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004; 43: 790-800
22.
Zurück zum Zitat Maverakis E et al. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts. JAMA Dermatol. 2018; 154: 461-6 Maverakis E et al. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts. JAMA Dermatol. 2018; 154: 461-6
23.
Zurück zum Zitat Marzano AV et al. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br J Dermatol. 2016; 175: 882-91 Marzano AV et al. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br J Dermatol. 2016; 175: 882-91
24.
Zurück zum Zitat Kontos AP et al. An open-label study of topical tacrolimus ointment 0.1% under occlusion for the treatment of pyoderma gangrenosum. Int J Dermatol. 2006; 45: 1383-5 Kontos AP et al. An open-label study of topical tacrolimus ointment 0.1% under occlusion for the treatment of pyoderma gangrenosum. Int J Dermatol. 2006; 45: 1383-5
25.
Zurück zum Zitat Ben Abdallah H et al. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review. Int Wound J. 2019; 16: 511-21 Ben Abdallah H et al. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review. Int Wound J. 2019; 16: 511-21
26.
Zurück zum Zitat Herberger K et al. Biologics and immunoglobulins in the treatment of pyoderma gangrenosum - analysis of 52 patients. J Dtsch Dermatol Ges. 2019; 17: 32-41 Herberger K et al. Biologics and immunoglobulins in the treatment of pyoderma gangrenosum - analysis of 52 patients. J Dtsch Dermatol Ges. 2019; 17: 32-41
27.
Zurück zum Zitat Kolios AG et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol. 2015; 173: 1216-23 Kolios AG et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol. 2015; 173: 1216-23
28.
Zurück zum Zitat Szatkowski J et al. Acute generalized exanthematous pustulosis (AGEP): A review and update. J Am Acad Dermatol. 2015; 73: 843-8 Szatkowski J et al. Acute generalized exanthematous pustulosis (AGEP): A review and update. J Am Acad Dermatol. 2015; 73: 843-8
29.
Zurück zum Zitat Sneddon IB et al. Subcorneal pustular dermatosis. Br J Dermatol 1956; 68: 385-94 Sneddon IB et al. Subcorneal pustular dermatosis. Br J Dermatol 1956; 68: 385-94
30.
Zurück zum Zitat Watts PJ et al. Subcorneal Pustular Dermatosis: A Review of 30 Years of Progress. Am J Clin Dermatol 2016; 17: 653-71 Watts PJ et al. Subcorneal Pustular Dermatosis: A Review of 30 Years of Progress. Am J Clin Dermatol 2016; 17: 653-71
31.
Zurück zum Zitat Sanchez N et al. Subcorneal pustular dermatosis: a variant of pustular psoriasis. Acta Derm Venereol Suppl (Stockh) 1979; 59: 147-51 Sanchez N et al. Subcorneal pustular dermatosis: a variant of pustular psoriasis. Acta Derm Venereol Suppl (Stockh) 1979; 59: 147-51
32.
Zurück zum Zitat Ratnarathorn M et al. Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) occurring in association with nodal marginal zone lymphoma: a case report. Dermatol Online J 2008; 14: 6 Ratnarathorn M et al. Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) occurring in association with nodal marginal zone lymphoma: a case report. Dermatol Online J 2008; 14: 6
33.
Zurück zum Zitat Kretschmer L et al. Interruption of Sneddon-Wilkinson Subcorneal Pustulation with Infliximab. Case Rep Dermatol 2017; 9: 140-44 Kretschmer L et al. Interruption of Sneddon-Wilkinson Subcorneal Pustulation with Infliximab. Case Rep Dermatol 2017; 9: 140-44
34.
Zurück zum Zitat Gooderham MJ et al. An update on generalized pustular psoriasis.Expert Rev Clin Immunol. 2019; 15: 907-19 Gooderham MJ et al. An update on generalized pustular psoriasis.Expert Rev Clin Immunol. 2019; 15: 907-19
35.
Zurück zum Zitat Booij MT et al. Acitretin revisited in the era of biologics. J Dermatolog Treat. 2011; 22: 86-9 Booij MT et al. Acitretin revisited in the era of biologics. J Dermatolog Treat. 2011; 22: 86-9
36.
Zurück zum Zitat Onoufriadis A et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011; 89: 432-7 Onoufriadis A et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011; 89: 432-7
37.
Zurück zum Zitat Sugiura K et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol. 2013; 133: 2514-21 Sugiura K et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol. 2013; 133: 2514-21
38.
Zurück zum Zitat Zhou J et al. An update on genetic basis of generalized pustular psoriasis (Review). Int J Mol Med. 2021; 47 Zhou J et al. An update on genetic basis of generalized pustular psoriasis (Review). Int J Mol Med. 2021; 47
39.
Zurück zum Zitat Mossner R et al. The genetic basis for most patients with pustular skin disease remains elusive. Br J Dermatol. 2018; 178: 740-8 Mossner R et al. The genetic basis for most patients with pustular skin disease remains elusive. Br J Dermatol. 2018; 178: 740-8
40.
Zurück zum Zitat Bachelez H et al. Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis. N Engl J Med. 2019; 380: 981-3 Bachelez H et al. Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis. N Engl J Med. 2019; 380: 981-3
41.
Zurück zum Zitat Benjegerdes KE et al. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016; 6: 131-44 Benjegerdes KE et al. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016; 6: 131-44
Metadaten
Titel
Fehlreguliertes angeborenes Immunsystem
Neutrophile Dermatosen
verfasst von
Steffen Schrenker
Prof. Dr. med. Luise Erpenbeck
Publikationsdatum
22.03.2022
Verlag
Springer Medizin
Erschienen in
hautnah dermatologie / Ausgabe 2/2022
Print ISSN: 0938-0221
Elektronische ISSN: 2196-6451
DOI
https://doi.org/10.1007/s15012-021-6823-5